Feels like an announcement to satisfy shareholder demands for more coms. Really, sales updates are only operational at this point so probably not something the asx would approve these days as a dedicated announcement. So the only other thing they'd be able to announce in this weird transitional period would be contracts signed for new CT agreements, submissions for further approvals, other tech upgrades, or progress on the band.
The trial agreements are really what most of us probably want to hear, but im wondering if they are being slowed by negative sentiment in the US as the new administration goes on the warpath against institutional health and pharma.
The environment over there is more in favour of recipe books by Pete Evans than of peer reviewed science, and that is going to cause challenges.
Add to My Watchlist
What is My Watchlist?
